Case study

Inferring causality of the microbiome in gastric ulceration

The Challenge

The faculty sought to understand how feed size and gastric microbiota contribute to ulcer development in pigs. Identifying causal relationships required advanced biostatistics and careful handling of complex microbiome data.

Our Approach

We built causal models, ensured rigorous quality control and derived insights to understand microbiome‑driven ulceration.

  • Hypothesis modelling & causal inference: Created a causal DAG from the client’s hypotheses and analysed relationships between feed size, microbial diversity, abundance and ulceration.
  • Quality control & annotation: De‑noised samples, annotated species and abundances, and produced publication‑ready visualisations.
  • Insights & publication: Performed mediation and differential abundance analyses to identify causal factors and suggest treatment strategies.

The Outcome

  • Provided interactive visualisations and causal insights that informed subsequent studies.
  • Published findings in a peer‑reviewed journal and extended academic collaboration.
  • Highlighted the importance of quality control and causal frameworks in microbiome research.

Why It Matters

Combining causal models with advanced biostatistics helps disentangle complex host–microbiome interactions. Such analyses guide interventions and improve understanding of disease mechanisms.

Let’s discuss how we can turn your data into real scientific impact.

Contact us >

Beyond animal testing in drug development

Beyond animal testing in drug development

For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.